Heart HealthCardiology & Heart Failure

Heart Failure with Preserved Ejection Fraction (HFpEF): Symptoms, Stiff Heart Muscle, and Treatment

Heart failure with preserved ejection fraction (HFpEF) occurs when the left ventricle becomes thick or stiff, preventing normal diastolic filling despite normal pumping capacity. Understand diagnostic markers like NT-proBNP, echocardiogram E/e' ratios, and evidence-based treatments including SGLT2 inhibitors and blood pressure control.

N
Written by Dr. Naresh Trehan, MBBS, MD, FACSChairman & Chief Cardiac Surgeon, Medanta – The Medicity
Medically Reviewed by Dr. Ashok Seth, MBBS, MD, FRCP, FACC✓ Verified
MBBS, MD, FRCP (London, Edin, Glasg), FACC• Reviewed September 2026•Medical Review Board
Published: 2026-09-02Reviewed: September 2026Updated: 2026-09-15 10 min read 1840 Views
Listen to this guide Audio Edition

Hands-free audio narration

Educational Health Notice

This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.

Heart Failure with Preserved Ejection Fraction (HFpEF): Symptoms, Stiff Heart Muscle, and Treatment

Quick Summary & Key Findings

HFpEF is diagnosed when patients have symptoms of heart failure (shortness of breath with exertion, ankle swelling, fatigue) alongside an ejection fraction of 50% or higher and elevated filling pressures (NT-proBNP >125 pg/mL, echocardiographic E/e' ratio >14). Modern medical management relies on SGLT2 inhibitors (empagliflozin, dapagliflozin), targeted loop diuretics for volume control, and tight blood pressure management.

In cardiovascular medicine, heart failure with preserved ejection fraction (HFpEF)—often termed diastolic heart failure—accounts for roughly half of all clinical heart failure hospitalizations. Unlike reduced ejection fraction heart failure (HFrEF), where the myocardium cannot squeeze blood out effectively, patients with HFpEF maintain a normal or near-normal left ventricular ejection fraction (LVEF ≥ 50%).

The fundamental pathophysiology lies in diastolic dysfunction: the walls of the left ventricle become stiff, fibrotic, or hypertrophied. During the filling phase of each heartbeat, the ventricle cannot relax adequately, causing pressure to back up into the left atrium and pulmonary circulation. Patients experience progressive shortness of breath during modest physical exertion, chronic fatigue, and peripheral fluid retention.

Early identification is critical because chronic hypertension, obesity, type 2 diabetes, and atrial fibrillation directly accelerate ventricular stiffness. With recent clinical trials demonstrating significant mortality and hospitalization reductions using SGLT2 inhibitors, managing HFpEF has shifted from purely symptomatic fluid removal to proactive disease modification.

Pathophysiology: Why Diastolic Relaxation Fails

Under normal physiological conditions, the left ventricle expands effortlessly during diastole to accommodate incoming oxygenated blood from the left atrium under low pressures. In HFpEF, chronic metabolic inflammation, microvascular endothelial dysfunction, and interstitial collagen deposition alter the titin protein springs within heart muscle cells. As myocardial compliance drops, left ventricular end-diastolic pressure (LVEDP) climbs rapidly even with small increases in blood volume. This elevated pressure transmits backward into the pulmonary veins, producing pulmonary capillary congestion (causing dyspnea) and systemic venous hypertension (causing lower extremity edema and hepatic congestion).
Impaired Active Relaxation: Early diastole requires active ATP-dependent calcium reuptake into the sarcoplasmic reticulum; metabolic dysfunction slows this process.
Passive Ventricular Stiffness: Interstitial fibrosis and hyperphosphorylated titin stiffen the myocardial wall during late diastole.
Elevated Pulmonary Pressures: Backward transmission of left atrial pressure leads to secondary post-capillary pulmonary hypertension.
Chronotropic Incompetence: Many HFpEF patients cannot increase their heart rate appropriately during exercise, worsening exertional fatigue.

Diagnostic Testing: Labs, Biomarkers, and Echocardiography

Confirming HFpEF requires objective demonstration of elevated filling pressures or structural diastolic abnormalities alongside clinical symptoms. Relying on ejection fraction alone can result in missed diagnoses.
N-Terminal Pro-BNP (NT-proBNP): Serum levels >125 pg/mL in sinus rhythm (or >365 pg/mL in atrial fibrillation) signal ventricular wall stress, though levels can be falsely lower in obese patients.
Transthoracic Echocardiogram (TTE): Measures the E/e' ratio (mitral inflow velocity divided by tissue Doppler mitral annular velocity). An E/e' ratio >14 indicates elevated left atrial pressure.
Left Atrial Volume Index (LAVI): A LAVI >34 mL/m² reflects chronic volume and pressure overload.
H2FPEF Risk Score: A clinical scoring tool integrating heavy weight (BMI >30), 2+ antihypertensive drugs, atrial fibrillation, pulmonary hypertension, elderly age (>60), and elevated filling pressures.

Evidence-Based Medical Therapy and Lifestyle Strategies

Clinical guidelines from the American College of Cardiology (ACC) and European Society of Cardiology (ESC) establish clear therapeutic priorities for HFpEF:
SGLT2 Inhibitors: Empagliflozin (10 mg daily) and Dapagliflozin (10 mg daily) hold Class 1 recommendations, reducing cardiovascular death and heart failure hospitalizations regardless of diabetic status.
Loop Diuretics (Furosemide, Torsemide): Used dynamically to maintain euvolemia and relieve pulmonary congestion and peripheral edema.
Mineralocorticoid Receptor Antagonists (MRAs): Spironolactone helps reduce myocardial fibrosis and blood pressure in select patients with elevated BNP.
Rigorous Blood Pressure Control: Targeting systolic blood pressure <130 mmHg prevents further left ventricular remodeling.
Weight Reduction & Structured Aerobic Exercise: Losing 5–10% body weight reduces pericardial restraint and systemic vascular resistance.
Caution
HFpEF patients are exquisitely sensitive to fluid shifts. Gaining 2 to 3 pounds in 24 hours or 5 pounds in a week signals acute fluid retention rather than body fat, requiring prompt diuretic dose adjustment by a healthcare provider before acute pulmonary edema develops.

Frequently Asked Questions

A
Clinical Reviewer License Verified

Dr. Ashok Seth, MBBS, MD, FRCP, FACC

Chairman, Fortis Escorts Heart Institute & Lead Interventional Cardiologist • MBBS, MD, FRCP (London, Edin, Glasg), FACC
Medical Review Board

Dr. Ashok Seth is the Chairman of Fortis Escorts Heart Institute, Okhla, New Delhi, and one of the world's foremost interventional cardiologists. He has pioneered cutting-edge techniques in coronary angioplasty, TAVR/TAVI, and directional atherectomy with over 35 years of clinical practice.

License ID: DMC-08421
Chairman, Fortis Escorts Heart Institute, Okhla Road, New Delhi
Medically evaluated on September 2026View Dr. Profile, Verified Credentials & Articles

References & Clinical Resources

  1. Clinical Research Faculty & Editorial Team. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2020-2026). [Access Resource Link] — Circulation / American Heart Association
  2. Clinical Research Faculty & Editorial Team. Empagliflozin in Heart Failure with a Preserved Ejection Fraction (EMPEROR-Preserved) (2020-2026). [Access Resource Link] — New England Journal of Medicine
  3. Clinical Research Faculty & Editorial Team. Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction (2020-2026). [Access Resource Link] — Nature Reviews Cardiology
Article Tools & Sharing:
Educational Resources
Patient Community Doctor Reviewed

Reader Reviews & Clinical Q&A

Real experiences, reader questions, and verified physician guidance.

5.0 out of 5 (3 reviews)
MT
Marcus T., Cardiology PatientVerified Patient
•August 18, 2026

This guide broke down the exact diagnostic thresholds and medication pathways so clearly. My cardiologist recently discussed adjusting my regimen, and reading this helped me prepare specific questions for my follow-up visit.

Dr. Ashok Seth, MBBS, MD, FRCP, FACCInterventional Cardiologist & Medical Reviewer
August 19, 2026

Thank you for sharing, Marcus. Preparing targeted questions beforehand makes clinical consultations far more productive. Always discuss any dosage or timing adjustments directly with your attending physician.

PL
Patricia L., Nurse PractitionerHealthcare Professional
•August 29, 2026

The structured comparison tables and ACC/AHA clinical trial references are outstanding. I frequently print sections of this guide to explain lifestyle modifications to patients in our outpatient clinic.

Dr. Ashok Seth, MBBS, MD, FRCP, FACCInterventional Cardiologist & Medical Reviewer
August 30, 2026

We are honored to support your clinical practice, Patricia. Translating complex cardiovascular guidelines into patient-friendly education is the core mission of our editorial board.

DK
David K.Verified Reader
•September 08, 2026

The distinction between acute emergency symptoms and chronic management gave me genuine peace of mind. Very well-written and easy to navigate on mobile.

Dr. Ashok Seth, MBBS, MD, FRCP, FACCInterventional Cardiologist & Medical Reviewer
September 09, 2026

Glad this provided clarity, David. Knowing the exact red-flag symptoms that require urgent care empowers patients to act decisively when it matters most.

Leave a Review or Ask a Medical Question

5 / 5 Stars
* Reviews are reviewed by our clinical editorial team in accordance with our medical policies.